Phase 1
PhaseBio Pharmaceuticals, Inc. announced that results from the Phase 1 clinical trial of PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, demonstrated that PB2452 provided immediate and sustained reversal of ticagrelor antiplatelet effects without report of drug-related serious adverse events.
In addition to the planned BioNTech IPO, many other pharma and biotech companies in Europe, Asia and elsewhere shared news for the week.
The FDA, as part of efforts to update clinical trial eligibility criteria, published four draft guidance documents on cancer clinical trial criteria and one final draft on adolescents in adult oncology trials.
TLC Reports Positive Top-Line Results from Phase I/II Clinical Trial of TLC590 for Postsurgical Pain
TLC590 demonstrated durable, statistically significant and clinically meaningful improvement over the standard of care through 96 hours
Following last year’s stellar initial public offering in October, where it raised $80.5 million, about $10 million over initial expectations, LogicBio Therapeutics is planning a gene-editing clinical trial in children.
Forendo Pharma today announces that it has successfully completed Phase 1a study of FOR-6219, an HSD17B1 inhibitor for the treatment of endometriosis.
Karolinska Development’s portfolio company Forendo Pharma today announces positive results from a Phase Ia study with the drug candidate FOR 6219 for the treatment of endometriosis.
This year could be the big year for the company. Its chief executive officer and president, Isaac Ciechanover, is leaving the company by June 30, but says 2019 could be transformative.
Biotech and pharma companies from across the globe share data and news in a weekly roundup.
Coming off its record-breaking initial public offering (IPO) in December, where it raised $604.3 million, Moderna released its fourth-quarter financials, outlining an ambitious company buzzing with activity.
PRESS RELEASES